Reference

In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci

All Rights Reserved. Some chemicals with cas registry numbers like 220620-09-7 and 100986-85-4 are also used. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Garrison, Mark W.; Nuemiller, Joshua J. (Washington State University, College of Pharmacy and Deaconess Medical Center, Spokane, WA 99210, USA). International Journal of Antimicrobial Agents, 29(2), 191-196 (English) 2007 Elsevier B.V. CODEN: IAAGEA. ISSN: 0924-8579. DOCUMENT TYPE: Journal CA Section: 10 (Microbial, Algal, and Fungal Biochemistry) Tigecycline is a glycylcycline with promising broad-spectrum activity, including resistant Gram-pos. organisms. This study characterizes in vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae (QRSP), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE). An in vitro pharmacodynamic model generated specific bacterial kill profiles for tigecycline against clin. isolates of QRSP, MRSA and VRE. Tigecycline produced a 6.6 log total redn. and cleared QRSP from the pharmacodynamic model by 18 h. Tigecycline and vancomycin were unable to achieve 3-log redns. in the MRSA and VRE isolates; log redns. in MRSA and VRE were 1.5 and 1.2 logs for tigecycline and 2.8 and zero for vancomycin, resp. Area under the concn. time curve to min. inhibitory concn. (AUC/MIC) values for tigecycline ranged from 79 to 158 mg h/mL and tigecycline concns. remained above the MIC (T > MIC) throughout the simulated dosing interval. Tigecycline showed in vitro activity against the QRSP, MRSA and VRE isolates studied. Low MIC values, prolonged elimination half-life and the assocd. post-antibiotic effect (PAE) obsd. with tigecycline are desirable attributes that make it a potentially attractive option for treating resistant Gram-pos. organisms. .

In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains

All Rights Reserved. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Katsandri, Anastasia; Avlamis, Athina; Pantazatou, Angeliki; Petrikkos, Georgios L.; Legakis, Nicholas J.; Papaparaskevas, Joseph ( Department of Microbiology, Laikon General Hospital, Athens 11527, Greece). Diagnostic Microbiology and Infectious Disease, 55(3), 231-236 (English) 2006 Elsevier Inc. CODEN: DMIDDZ. ISSN: 0732-8893. DOCUMENT TYPE: Journal CA Section: 10 (Microbial, Algal, and Fungal Biochemistry) Section cross-reference(s): 14 The in vitro activity of tigecycline was compared with those of benzylpenicillin, piperacillin + tazobactam, cefoxitin, imipenem, metronidazole, clindamycin, and tetracycline against 249 Gram-neg. anaerobic bacteria (158 Bacteroides fragilis group, 27 non-fragilis Bacteroides spp., 44 Prevotella spp., and 20 misc.In this article, certain chemicals are used. Some of their cas registry numbers are 220620-09-7 and 64221-86-9 ), recently isolated from 8 general hospitals in Athens, Greece. Overall tigecycline MIC50 and MIC90 were 0.25 and 2 mg/L, resp., whereas B. fragilis group MIC50 and MIC90 were 0.5 and 4 mg/L, resp. In total, 93% of the isolates were susceptible to tigecycline (MIC ￡ 4 mg/L) and no high-level resistance (MIC 3 32 mg/L) was detected. In addn., tigecycline exhibited good activity against metronidazole- and tetracycline-resistant isolates (MIC90, 0.5 and 8 mg/L, resp.). In summary, tigecycline exhibits good in vitro activity against Gram-neg. anaerobic bacteria isolated in Greece, as well as stability to the most common occurring resistance mechanisms, attributes that make this parenteral agent an attractive alternative for use against infections involving these microorganisms. .